The lancet oncology

• Latest
• Best
• Search…

• The lancet oncology · Sep 2014

  Multicenter Study

  Adapted paediatric regimen benefits adults with ALL.

  no abstract available

  expand abstract… mark as read…

• The lancet oncology · Sep 2014

  Comparative Study

  NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer.

  no abstract available

  read more… or not…

• The lancet oncology · Sep 2014

  Comment

  Dual targeting of HER2 with lapatinib and trastuzumab.

  no abstract available

  keep going… or not…

• The lancet oncology · Sep 2014

  Comment

  Role of bisphosphonates in non-metastatic prostate cancer.

  no abstract available

  expand abstract… or not…

• The lancet oncology · Sep 2014

  Randomized Controlled Trial Multicenter Study Comparative Study

  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

  Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (FOLFIRI) is unknown. We aimed to compare these agents in patients with KRAS (exon 2) codon 12/13 wild-type metastatic colorectal cancer. ⋯ Merck KGaA.

  read more… mark as read…